UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHA TM Phase 1 heme trial ...

FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fo ...

Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair "We are pleased to welcome Garry to our Board of Directors. He has a breadth of experience in oncology development and commercialization spanning more than 35 years, including serving as president of Pfizer Oncology where he led its global oncology franchise," said Gavin MacBeath, Ph.D., Chief Executive Officer. "Garry has extensive expertise in operations, sales, regulatory strategy, and commercialization, and we look ...

Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair Mr. Nicholson has more than 35 years of pharmaceutical and biotech oncology experience. Mr. Nicholson currently serves as chairman of the board of directors for G1 Therapeutics, Day One Biopharmaceuticals and Abdera Therapeutics. He also previously served on the board of directors for Turning Point Therapeutics, Five Prime Therapeutics, Tmunity and TESARO prior to their acquisitions by large pharmaceutical companies. A ...

WALTHAM, Mass, May 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TSC-100 and TSC-101, the Company's two lead TCR-T therapy candidates for the treatment of heme malignancies (NC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | For the transition period from _____________________________to_____________________________________________________ | | | --- | --- | | Commission File Number: 001-40603 | | | TSCAN THERA ...

Exhibit 99.1 TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 WALTHAM, Mass., Ma ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of Registrant as specified in its Charter) Delaware 82-5282075 (State or other jurisdiction of incorporation or organization) 830 Winter Street Waltham, Massachusetts 02451 (Address of principal executive offices) (Zip Code) For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT T ...

Exhibit 99.1 TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism Announced the clearance of two additional INDs for Solid Tumor Program: TSC-201-B0702 targeting MAGE- C2 on HLA-B*07:02 and TSC-204-A0101 targetin ...